Abstract
The FP2020 market grew from US$277 million in 2011 to US$361 million in 2012 and then declined to US$280 million in 2013. The FP2020 market grew 30 percent year-over-year in 2012, largely driven by a shift in method mix in favor of injectables and implants, which have higher unit costs relative to other methods. The implant price reductions in 2013, combined with decreased purchase volumes of male condoms, injectables, IUDs, and orals, reduced the 2013 FP2020 market size to 2011 levels.
Short-acting methods (including condoms, injectables, and oral contraceptives) continue to dominate the FP2020 market despite a significant increase in implant purchase volumes. Short-acting methods represented 80 percent of the total FP2020 market value in 2013, but represented 62 percent of couple-years of protection (CYPs) supplied.2 Implant purchase volumes have nearly doubled between 2011 and 2013 to 6 million units annually. The estimated spend on implants and IUDs, long-acting and reversible contraceptives (LARCs), was US$55 million in 2013, representing 20 percent of the total FP2020 market value and 38 percent of CYPs provided.
